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Longitudinal association between CRP levels and risk of
psychosis: a meta-analysis of population-based cohort studies
Emanuele F. Osimo 1,2,3,18✉, Luke Baxter4,18, Jan Stochl1,5, Benjamin I. Perry1,3, Stephen A. Metcalf 6, Setor K. Kunutsor7,8,
Jari A. Laukkanen9,10,11, Marie Kim Wium-Andersen12,13,14, Peter B. Jones 1,3,15 and Golam M. Khandaker1,3,15,16,17✉
Meta-analyses of cross-sectional studies suggest that patients with psychosis have higher circulating levels of C-reactive protein
(CRP) compared with healthy controls; however, cause and effect is unclear. We examined the prospective association between CRP
levels and subsequent risk of developing a psychotic disorder by conducting a systematic review and meta-analysis of population-
based cohort studies. Databases were searched for prospective studies of CRP and psychosis. We obtained unpublished results,
including adjustment for age, sex, body mass index, smoking, alcohol use, and socioeconomic status and suspected infection
(CRP > 10mg/L). Based on random effect meta-analysis of 89,792 participants (494 incident cases of psychosis at follow-up), the
pooled odds ratio (OR) for psychosis for participants with high (>3mg/L), as compared to low (≤3mg/L) CRP levels at baseline was
1.50 (95% confidence interval [CI], 1.09–2.07). Evidence for this association remained after adjusting for potential confounders
(adjusted OR [aOR]= 1.31; 95% CI, 1.03–1.66). After excluding participants with suspected infection, the OR for psychosis was 1.36
(95% CI, 1.06–1.74), but the association attenuated after controlling for confounders (aOR= 1.23; 95% CI, 0.95–1.60). Using CRP as a
continuous variable, the pooled OR for psychosis per standard deviation increase in log(CRP) was 1.11 (95% CI, 0.93–1.34), and this
association further attenuated after controlling for confounders (aOR= 1.07; 95% CI, 0.90–1.27) and excluding participants with
suspected infection (aOR= 1.07; 95% CI, 0.92–1.24). There was no association using CRP as a categorical variable (low, medium or
high). While we provide some evidence of a longitudinal association between high CRP (>3 mg/L) and psychosis, larger studies are
required to enable definitive conclusions.
npj Schizophrenia            (2021) 7:31 ; https://doi.org/10.1038/s41537-021-00161-4
INTRODUCTION
Several lines of evidence implicate infection and inflammation in
the pathogenesis of schizophrenia and related psychotic dis-
orders. First, childhood infections involving the central nervous
system1,2, and particularly viral infections1,3, are associated with a
nearly twofold risk of adult schizophrenia4. Second, meta-analyses
of population-based longitudinal studies suggest that prenatal
maternal infection, including bacterial5, respiratory6, or genital and
reproductive infections5,7,8, are associated with a two- to fivefold
increased risk of schizophrenia in the offspring. Third, meta-
analyses of cross-sectional studies have reported raised levels of
several inflammatory markers and elevated specific cell counts in
patients with schizophrenia as compared to controls9–16.
C-reactive protein (CRP) is an acute-phase protein and an
archetypal inflammatory marker that has been used most
extensively as a proxy for systemic inflammation in studies of
physical17,18 and psychiatric disorders14,19–25. Meta-analyses of
cross-sectional studies reported that circulating CRP levels are
higher in schizophrenia compared to healthy controls, with
medium to large effect sizes13,14,26. Our recent meta-analysis15
supports small to medium effect sizes in medication-naïve first-
episode psychosis patients. However, cross-sectional studies
cannot ascertain the direction of the association, i.e., whether
elevated CRP predates or follows psychosis.
Longitudinal studies can disentangle the directionality of the
association between exposure and outcome, and therefore can
help to address the issue of reverse causation27. Furthermore,
population-based longitudinal studies are less prone to sampling
bias, a common issue for cross-sectional designs, which often
include hospitalized patients27. A number of population-based
studies have reported a longitudinal association between higher
CRP levels at baseline and risk of psychosis at follow-up28–34.
However, there are important issues that need to be considered to
allow more definitive conclusions. For example, there is hetero-
geneity in sample age with some studies conducted in relatively
young29,31–34 and some in relatively older populations28,30. While
these studies have controlled for various confounders, variables
included varied from study to study. Third, not all studies excluded
participants with suspected infection, as measured by a fixed CRP
threshold28,30,33. Therefore, a more streamlined analysis across
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cohorts with consistent adjustment for key confounders is
required.
In this study, we aimed to examine the longitudinal associa-
tions between circulating CRP levels and subsequent risk of
psychotic disorders by carrying out a systematic review and
meta-analysis of population-based prospective studies. We
examined the nature of this longitudinal association in a number
of ways. First, we used CRP both as a continuous and a binary
variable. For the latter, we defined CRP levels >3 mg/L as “high”
in line with the American Heart Association and the US Centers
for Disease Control and Prevention criteria for CRP use in
population-based research35, and in line with previous psychia-
tric research20–22. Second, to examine the potential effect of
confounding, we used results from each cohort before and after
adjusting for the same set of confounders including age, sex,
body mass index (BMI), measures of socioeconomic status (SES),
smoking, and alcohol use. We repeated the analysis after
excluding participants with baseline CRP levels >10 mg/L to
minimise potential confounding by acute inflammation/infec-
tion35. Finally, to examine the effect of age we carried out sub-
group analyses by age.
RESULTS
The literature search yielded 303 studies, out of which five met
the inclusion criteria28–31,34. Two of these studies examined the
associations of childhood CRP levels with the risk of psychotic
disorder in adulthood in the ALSPAC birth cohort29,34. Of the two,
we included the study with the longer follow-up34. Conse-
quently, four studies were included in meta-analysis28,30,31,34.
Please see Supplementary Fig. 1 for the PRISMA diagram of study
selection.
Description of cohort samples
The studies included in the meta-analysis comprised 89,792
participants, with 494 incident cases of psychosis, drawn from
separate areas of Europe. Please see Table 1 for study
characteristics. The studies had an average follow-up length of
14.55 years (SD= 7.58) for psychosis after CRP assessment at
baseline. Two studies involved relatively young adults with
psychosis from specific birth cohorts (mean age at outcome
assessment around 24–26 years)31,34, while two involved older
adults (mean age at the outcome of 64–78 years)28,30. Samples
were, on average, 60.2% male (range: 44.5–100%). The mean
percentage of white ethnicity across studies was 99.7% (range:
98.7–100%).
In the study by Perry et al.34, CRP was measured at age 9, and
psychosis was assessed at age 24 using a semi-structured face-to-
face interview (see Table 1 for details). Metcalf et al.31 used the
NFBC 1986 cohort, in which CRP was measured at age 16, and
psychosis were assessed up to age 27 using hospital inpatient,
hospital outpatient, and healthcare outpatient records. The study
by Wium-Andersen et al.28 included all register-based diagnoses
of all hospital contacts with schizophrenia or a psychotic disorder
from the Danish National Patient Registry, which includes in-
patient diagnoses since 1977. In addition, psychiatric out-patient
and emergency contacts since 1995 were also used to identify
potential cases. In this study CRP was measured on average at age
57, and incident psychosis was detected on average up to age 64.
The study by Laukkanen et al.30 included CRP measurements at a
mean age of 53 years and data on hospitalization due to a
psychotic disorder up to a mean age of 78 years, ascertained by
linkage to the National Hospital Discharge Register. Diagnoses of
psychotic disorders were made by qualified psychiatrists accord-
ing to ICD-8, -9, and -10 codes.
Laukkanen et al. and Wium-Andersen et al.28 both excluded
participants with psychosis at baseline. However, studies by Perry
et al.34 and Metcalf et al.31 did not exclude participants with
psychosis before CRP assessment at ages 9 and 16 years,
respectively.
Odds ratios (ORs) for psychosis at follow-up for individuals
with high baseline CRP (>3mg/L)
The meta-analytic unadjusted OR for psychosis at follow-up in
participants with high CRP (>3mg/L) as compared to low CRP
(≤3mg/L) at baseline was 1.50 (95% CI, 1.09–2.07, p= 0.01). Point
estimates were slightly larger for the childhood/adolescence
samples; see Fig. 1a. Evidence for this association remained after
adjusting for age, sex and BMI (adjusted pooled OR [aOR]= 1.44;
95% CI, 1.02–2.03; p= 0.04), and after additional adjustments for
alcohol consumption, smoking levels and SES (aOR= 1.31; 95% CI,
1.03–1.66; p= 0.03); see Fig. 1b, c.
There was no evidence of significant heterogeneity in any of the
analyses (all I2 between 0 and 39.8%; Cochran’s Qs between 1.6
and 4.1 (df= 3); all ps >0.25).
ORs for psychosis at follow-up per SD increase in baseline CRP
The meta-analytic unadjusted OR for psychosis at follow-up per SD
increase in baseline CRP as a continuous value was 1.11 (95% CI,
0.93–1.34, p= 0.24). See Fig. 2a. The 95% confidence interval
widened after adjusting for age, sex and BMI (aOR= 1.10 (95% CI
0.90–1.35, p= 0.36). The fully adjusted model showed a pooled OR
of 1.07 (95% CI, 0.90–1.27, p= 0.45); see Fig. 2b, c.
There was no evidence of significant heterogeneity in any of the
analyses (all I2 between 31 and 58%; Cochran’s Qs between 3.7
and 5.7 (df= 3); all ps >0.05).
ORs for psychosis at follow-up for individuals with high
(>3mg/L) and medium (1–3mg/L), as compared to low
(<1mg/L), CRP levels at baseline
Compared to those with low baseline CRP (<1mg/L), the OR for
psychosis at follow-up was 0.93 (95% CI, 0.68–1.27) for medium
(1–3mg/L) and 1.49 (95% CI, 0.95–2.32) for high (>3mg/L) CRP.
The overall pooled OR for psychosis for CRP ≥1mg/L as compared
to <1mg/L was 1.18 (95% CI, 0.88–1.59, p= 0.26).
After adjusting for all potential confounders, the aOR for the
medium CRP group was 0.90 (95% CI, 0.60–1.35) and that for the
high CRP group was 1.27 (95% CI, 0.84–1.94). The overall aOR for
CRP ≥1mg/L as compared to <1mg/L was 1.07 (95% CI, 0.79–1.43,
p= 0.67). See Supplementary Fig. 2.
Sensitivity analyses: ORs for psychosis at follow-up for
individuals with high baseline CRP (>3mg/L), excluding
subjects with suspected infection (CRP > 10mg/L) at baseline
After excluding subjects with suspected infection (CRP > 10mg/L)
at baseline, the meta-analytic unadjusted OR for psychosis at
follow-up in participants with high CRP (>3 mg/L) as compared to
low CRP (≤3mg/L) at baseline was 1.36 (95% CI, 1.06–1.74; p=
0.01); see Supplementary Fig. 3, panel A. Evidence for this
association weakened after adjusting for age, sex and BMI
(adjusted pooled OR= 1.27; 95% CI, 0.99–1.64; p= 0.06) and on
further adjustments for alcohol consumption, smoking levels and
SES (adjusted pooled OR= 1.23; 95% CI, 0.95–1.60; p= 0.12); see
Supplementary Fig. 3, panels B and C.
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Sensitivity analyses: ORs for psychosis at follow-up per SD
increase in baseline CRP as a continuous variable, excluding
subjects with suspected infection (CRP > 10mg/L) at baseline
After excluding subjects with suspected infection (CRP >
10 mg/L) at baseline, the meta-analytic unadjusted OR for
psychosis at follow-up per SD increase in baseline CRP was 1.07
(95% CI 0.92–1.24, p= 0.40); see Supplementary Fig. 4, panel A.
The 95% confidence interval widened after adjusting for age,
sex and BMI (aOR= 1.04; 95% CI, 0.88–1.24; p= 0.64). The fully
adjusted model showed a pooled OR of 1.00
(95% CI 0.88–1.13, p= 0.97); see Supplementary Fig. 4, panels
B and C.
Fig. 1 Odds ratios for psychosis at follow-up for individuals with high (>3mg/L), as compared to low (≤3mg/L), CRP levels at baseline.
a Unadjusted analysis; b adjusted for age, sex and BMI; c adjusted for age, sex, BMI, smoking, alcohol consumption and socioeconomic status.
* see “Methods” for specific covariates used for each study. BMI body mass index, CRP C-reactive protein, mg/L milligrams per litre.
E.F. Osimo et al.
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Sensitivity analyses: ORs for psychosis at follow-up for
individuals with high (>3mg/L) and medium (1–3mg/L), as
compared to low (≤1mg/L), CRP levels at baseline, excluding
subjects with suspected infection (CRP > 10mg/L) at baseline
After excluding subjects with suspected infection (CRP > 10mg/L)
at baseline, the results were similar to the primary analyses,
indicating no association between high or medium CRP levels and
psychosis risk (Supplementary Fig. 5).
Sensitivity analyses: study quality assessment
All included studies were rated ≥7 on the Newcastle-Ottawa Scale
for study quality (ref. 36; see Supplementary Table 1). After
Fig. 2 Odds ratios for psychosis at follow-up per SD increase in CRP levels at baseline. a Unadjusted analysis; b adjusted for age, sex and
BMI; c adjusted for age, sex, BMI, smoking, alcohol consumption and socioeconomic status. * see “Methods” for specific covariates used for
each study. BMI body mass index, CRP C-reactive protein, SD standard deviation.
E.F. Osimo et al.
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converting the scores into Agency for Healthcare Research and
Quality standards (good, fair, poor)15, all studies were rated as
‘good quality’.
DISCUSSION
In this study, we meta-analyzed data from four population-based
prospective studies comprising 89,792 participants and 494
incident cases of psychosis to examine the longitudinal associa-
tions between CRP at baseline and risk of psychosis at follow-up.
Our results suggest that high CRP levels at baseline (>3mg/L) are
associated with an increased risk of psychosis at follow-up.
However, we found no association between CRP and psychosis
using CRP as a continuous variable (per SD increase), or using CRP
as a categorical variable (low, medium or high). Overall, the effect
sizes were slightly larger for younger compared with older
samples, but our analysis included a limited number of studies
and a relatively small number of cases. Therefore, in the future
larger samples will be required before definitive conclusions can
be drawn about the true existence of longitudinal associations
between CRP and psychosis risk, and the potential effects of age
of onset.
Using CRP as a binary variable, we report an increase of 50% in
the odds of developing psychosis for those with high (>3mg/L), as
compared to low (≤3mg/L), CRP levels at baseline in unadjusted
analyses. The availability of unpublished results allowed us to
examine the effects of a number of important confounding
factors, including suspected infection (CRP > 10mg/L) at baseline
(time of blood sampling). In addition to sex, age and BMI, we
included relevant social and lifestyle factors, including alcohol
consumption, smoking, and SES. Our results suggest that evidence
for an association between high, as compared to low, CRP levels at
baseline and risk of psychosis at follow-up remained after
adjusting for potential confounders. After excluding participants
with suspected infection, defined as having CRP > 10mg/L at
baseline, the evidence for an association remained only in the
unadjusted, but not in the adjusted, analyses.
Our findings, that dichotomous CRP levels (>3mg/L) could be
longitudinally associated with a higher risk of psychosis, are
consistent with evidence from previous cross-sectional studies.
These have found elevated CRP levels in first-episode psychosis as
compared to healthy controls14,37, and in patients with chronic
schizophrenia13,38. CRP levels have also been reported to correlate
with psychotic symptom severity14. Potential explanations for the
null findings in sensitivity analyses excluding subjects with CRP >
10mg/L at baseline, and using CRP as a categorical variable (low,
medium and high), may include limited statistical power due to a
smaller number of cases overall, or in each category. We also
observe no associations using CRP as a continuous variable. It is
possible that the CRP-psychosis association is non-linear, as we
observe an association using CRP as a binary variable but not
using CRP as a continuous variable. In future, further studies with a
larger number of cases will be required to test whether an
association exists, and, if so if it is linear or non-linear.
A number of meta-analyses have reported that patients with
schizophrenia and related psychotic disorders have higher CRP
levels compared to controls13,14. Our findings are consistent with
these results. We provide some evidence for a longitudinal
association between high CRP levels at baseline and increased risk
of psychosis at follow-up. However, this epidemiological evidence
is at odds with recent findings from Mendelian randomization
(MR) studies that used genetic variants as proxies for CRP to
examine whether the CRP-psychosis association is likely to be
causal or could be attributable to confounding. Using genetic
variants associated with CRP levels, MR studies have reported that
genetically predicted higher CRP levels are associated with a
decreased risk of psychosis39–41. This is puzzling, given that case-
control studies have consistently reported higher CRP levels in
psychosis patients, and further research is required to understand
the exact mechanisms.
There may be a number of potential explanations for the
divergent findings between epidemiological and MR studies. For
instance, it has been proposed that a genetic predisposition for a
decreased acute phase response (as reflected by lower CRP levels)
might increase the risk of psychosis by increasing susceptibility to
infection40,42. The MR results could also be a consequence of not
taking into account other inflammatory markers that influence
CRP levels. For instance, a recent MR study by Perry and
colleagues reported that, after controlling for genetically pre-
dicted levels of IL-6, IL-6 remained associated with schizophrenia
while the apparent protective effect of CRP on schizophrenia risk
completely attenuated43. This highlights the importance of
considering the immune system as a highly interlinked and
complex entity rather than looking at individual biomarkers in
isolation.
Evidence supporting a role for inflammation in psychosis may
inform novel approaches to the treatment and prevention of this
condition. A meta-analysis of clinical trials of anti-inflammatory
drugs given as an adjunct to antipsychotics shows that the
addition of anti-inflammatories results in greater improvements in
positive and negative symptoms of psychosis, as compared to
antipsychotic monotherapy44. Further research is needed to test
whether treating inflammation has broader therapeutic benefits in
psychosis, and if the benefits might extend to all or just to a
subgroup of patients with psychosis.
Among the strengths of this work, all the included studies were
rated as “good quality” according to Agency for Healthcare
Research and Quality standards. There was little evidence of
heterogeneity in the meta-analyses. We used harmonized,
unpublished results from each cohort to specifically address
confounding, and we were able to run sensitivity analyses
excluding subjects with suspected infection. We examined
associations separately in cohorts including early- and late-onset
psychosis. Our choice of potential confounders was informed by
previous research. Both age45–47 and sex47,48 are separately
associated with schizophrenia risk and levels of CRP. A higher
BMI has been associated with increased CRP levels49,50, and BMI
shows differential associations with psychosis risk depending on
age. A low BMI in childhood is associated with an increased risk of
psychosis51. Patients with psychosis tend to have higher BMI as a
group possibly due to lifestyle and other factors, including
metabolic effects of certain antipsychotic drugs52. BMI levels have
also been associated with differing psychiatric outcomes in first-
episode psychosis53, though this association was not replicated54.
In addition, we included smoking and alcohol use as potential
confounders, both of which are known to increase levels of
inflammatory markers and are also associated with psychosis
risk55. Finally, SES is an important correlate of psychosis risk47.
Limitations of the work include the small number of studies
available to include in the meta-analysis. Therefore, formal
assessment of publication bias was not appropriate, as Cochrane
recommends that “tests for funnel plot asymmetry should be used
only when there are at least 10 studies included in a meta-
analysis”56.
Further, it is possible that studies with null findings were not
published. The limited number of studies also precluded the use
of meta-regression to explore further potentially confounding
effects such as age at onset, which was instead represented as an
exploratory subgroup analysis.
Our sample included a total of 494 incident cases of psychosis,
of which 114 had high CRP levels at baseline (>3mg/L), which
represents 23% of the psychosis sample. This is very close to the
meta-analytic estimate of the prevalence of high CRP in psychosis
(28% in ref. 13, a meta-analysis including both inpatient and
community samples), and in depression (24% in ref. 20, in a
sensitivity analysis of community samples only).
E.F. Osimo et al.
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Most study participants were of white ethnicity, which favours
comparability of the included studies, but makes it less generalizable
to other ethnicities, especially given the significant role of non-white
ethnicity both on the risk of psychosis47 and on CRP levels57.
Furthermore, the studies included substantial levels of hetero-
geneity with regard to the estimated incidence of psychosis.
Incidence estimates varied between 0.16 and 10.05% between
included samples, which can be partially attributed to notable
differences in age, duration of follow-up, and outcome definition
and method for case ascertainment. For instance, the average age
at the outcome for two studies was in the mid-twenties31,34,
whereas for two other studies, it was in the mid-sixties to late
seventies28,30. Furthermore, follow-up durations in these studies
ranged from 7.3 to 24.9 years, with Laukkanen et al. having the
longest follow-up and showing the highest incidence of psychosis,
and Wium-Andersen et al. having the shortest follow-up and
showing the lowest incidence. With regard to the outcome
assessments, the cohorts used by Wium-Andersen et al., with the
lowest incidence, likely overlooked some community diagnoses as
these can be made in private practice in Denmark, and could
therefore be missed in national registries. However, these
substantial overall differences in incidence did not translate into
statistically significant heterogeneity in ORs for the main outcome,
therefore suggesting that inflammation might have played a
similar role in all included cohorts.
Finally, however similarly to most previous research in
immunopsychiatry, the included studies only measured CRP at
baseline once, so this one measure may not accurately reflect
long-term variability in CRP levels.
In conclusion, this meta-analysis of four prospective, population-
based studies provides some evidence for a longitudinal association
between high CRP levels (>3mg/L) at baseline and greater risk for
developing psychosis at follow-up. There was some indication that
the effect sizes were larger for younger compared with older
samples. However, these analyses included a limited number of
cases of psychosis, and the results using CRP as continuous or
categorical variables were largely null. In future, further studies with
a larger number of cases are required before definitive conclusions




We conducted a systematic review in line with the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines58. Two separate databases, PubMed and
Google Scholar, were searched from their inception to the 1st of
September 2020 for published, prospective studies of CRP levels
and schizophrenia or related psychoses using the following search
terms (* denotes wildcard terms):
(longitudinal OR cohort OR prospective*) AND (CRP OR “C-
reactive protein” OR hs-CRP) AND (schizophreni* OR psychosis OR
psychotic).
Google Scholar was used as a source of grey literature59. As
suggested in ref. 59, the first 200 search results from Google
Scholar were screened. The search was limited to studies based on
human participants. The electronic search was complemented by
hand-searching of meta-analyses and review articles and by
contacting study authors. Abstracts were screened, and full texts
of relevant studies were retrieved.
Selection criteria
The inclusion criteria were:
● Longitudinal study design with data on CRP at baseline and psychosis
at follow-up.
● CRP levels measured in plasma or serum at baseline using a standard
laboratory method.
● Psychosis or schizophrenia assessed at follow-up using a standardized
methodology; e.g., interview-assessed, or clinical diagnosis from
electronic health records.
● Population-based samples, e.g., cohort or community-based, repre-
sentative of the general population.
The exclusion criteria were:
● Cross-sectional studies or longitudinal studies based on particular
groups of individuals selected on the basis of, e.g., a specific
demographic characteristic, diagnosis of a certain disease/disorder,
or a specific infection.
● Non-human subjects.
● Studies exclusively based in settings other than community (e.g.,
hospitalized).
When multiple articles were identified from a single cohort, the
article with the largest sample or longest follow-up was included.
Two authors (LB and EFO) independently applied the inclusion/
exclusion criteria and selected the final studies for this review.
Data extraction including collection of unpublished results
For each study, we extracted information on the OR for psychosis
at follow-up, sample size, number of incident cases of psychosis at
follow-up, length of follow-up, cohort, method of case ascertain-
ment, country, age at baseline (CRP sampling), age at follow-up
(psychosis diagnosis), sex, ethnicity, and definition of outcome.
We contacted all corresponding authors of the included studies
and requested unpublished results. Specifically, for each study, we
obtained the ORs for psychosis at follow-up associated with
baseline CRP levels, coding CRP as:
● a binary variable (>3mg/L versus ≤3mg/L);
● a continuous variable, after log-transformation to correct right skew
(per standard deviation [SD] increase);
● a categorical variable (≤1mg/L [reference]; >1 and ≤3mg/L; >3 mg/L.
ORs were obtained both before and after adjustments for
potential confounding by age, sex, BMI; and after further
adjustment for smoking, alcohol consumption, and SES, if
available. These were selected as potential confounders as they
are associated with psychosis and inflammation (please see
discussion). Authors were also asked to provide unadjusted and
adjusted ORs after excluding subjects with potential infection at
baseline (defined as CRP > 10mg/L). In addition, in the study by
Wium-Andersen et al.28 ORs were adjusted for type of CRP assay,
as two different methods were used for analysing CRP levels.
Wium-Andersen et al. used education and income levels as
measures for SES, while Metcalf et al. used maternal education
levels as a proxy for SES. Perry et al. had no alcohol and smoking
data available at baseline at the time of exposure measurement.
However, since the exposure was measured at age 9 y, it is unlikely
that many participants would have smoked or regularly consumed
alcohol in this sample.
The methodological quality of each included study was
assessed using the Newcastle-Ottawa Scale (NOS) for cohort
studies36,60.
Data synthesis and statistical analysis
Random effects models were used to meta-analyse ORs in order to
address differences due to methodology and sample size. ORs
were used as the preferred statistic over others (e.g., hazard ratios),
due to uncertainties around the exact time of outcome in some
samples. For instance, ALSPAC cohort participants34 were assessed
for psychosis at age 24, but it is unclear when the outcome had
first occurred. Register-based studies often relied on hospitaliza-
tion primarily to identify cases28,30,31. While hospitalization is a
useful proxy for illness time of onset, it may still not accurately
reflect exact time of onset as not all patients are hospitalized and
E.F. Osimo et al.
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often there is a considerable delay between illness manifestation
and help-seeking from healthcare professionals.
Random effects models were fitted using the restricted
maximum-likelihood estimator, which has been shown to be
effective in small meta-analytic samples where sample sizes are
significantly diverse61. ORs were log-transformed for meta-
analysis and then back-transformed for plotting in forest plots.
Meta-analyses of ORs were carried out using the metafor
package62 in R63.
Heterogeneity between studies was measured using the I2
statistic, which reflects the percentage of the variability in effect
estimates that is due to heterogeneity. Heterogeneity was tested
using Cochran’s Q Test64. p < 0.05 two tailed was considered
statistically significant. Publication bias could not be assessed due
to the small number of included studies.
DATA AVAILABILITY
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